These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8118399)

  • 1. Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC).
    Lu Z; Douthitt MP; Taffs RE; Ran Y; Norwood LP; Chumakov KM
    PCR Methods Appl; 1993 Dec; 3(3):176-80. PubMed ID: 8118399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPREC assay for quantitation of mutants in a recombinant flavivirus vaccine strain using near-infrared fluorescent dyes.
    Bidzhieva B; Laassri M; Chumakov K
    J Virol Methods; 2011 Jul; 175(1):14-9. PubMed ID: 21514323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods to Monitor Molecular Consistency of Oral Polio Vaccine.
    Chumakov KM
    Methods Mol Biol; 2016; 1387():263-77. PubMed ID: 26983740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence.
    Chumakov KM; Norwood LP; Parker ML; Dragunsky EM; Ran YX; Levenbook IS
    J Virol; 1992 Feb; 66(2):966-70. PubMed ID: 1309923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the neurovirulence of poliovirus by non-radioisotope molecular analysis to quantify genomic changes.
    Horie H; Tano Y; Doi Y; Hashizume S
    Biologicals; 1998 Dec; 26(4):289-97. PubMed ID: 10403032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay.
    Gnanashanmugam D; Falkovitz-Halpern MS; Dodge A; Fang M; Wong LJ; Esparza M; Hammon R; Rivas-Merelles EE; Santos JI; Maldonado Y
    J Clin Microbiol; 2007 Aug; 45(8):2419-25. PubMed ID: 17581940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of molecular biological method (MAPREC-test) for evaluating residual neurovirulence and genetic stability of oral poliovirus vaccine type 3].
    Rumiantsev AA; Grachev VP; Kozlov VG; Karganova GG
    Vopr Virusol; 2001; 46(6):11-5. PubMed ID: 11785380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-specific PCR for quantitative analysis of mutants in live viral vaccines.
    Bidzhieva B; Laassri M; Chumakov K
    J Virol Methods; 2014 Jun; 201():86-92. PubMed ID: 24607431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying low-frequency revertants in oral poliovirus vaccine using next generation sequencing.
    Sarcey E; Serres A; Tindy F; Chareyre A; Ng S; Nicolas M; Vetter E; Bonnevay T; Abachin E; Mallet L
    J Virol Methods; 2017 Aug; 246():75-80. PubMed ID: 28456668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions.
    Taffs RE; Chumakov KM; Rezapkin GV; Lu Z; Douthitt M; Dragunsky EM; Levenbook IS
    Virology; 1995 Jun; 209(2):366-73. PubMed ID: 7778271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.
    Neverov A; Chumakov K
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20063-8. PubMed ID: 21041640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.
    Rezapkin GV; Chumakov KM; Lu Z; Ran Y; Dragunsky EM; Levenbook IS
    Virology; 1994 Jul; 202(1):370-8. PubMed ID: 8009849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation between vaccine-related and wild-type polioviruses using a heteroduplex mobility assay.
    Chezzi C; Schoub BD
    J Virol Methods; 1996 Dec; 62(2):93-102. PubMed ID: 9002067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consistent selection of mutations in the 5'-untranslated region of oral poliovirus vaccine upon passaging in vitro.
    Chumakov KM; Dragunsky EM; Norwood LP; Douthitt MP; Ran Y; Taffs RE; Ridge J; Levenbook IS
    J Med Virol; 1994 Jan; 42(1):79-85. PubMed ID: 8308524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis.
    Furione M; Guillot S; Otelea D; Balanant J; Candrea A; Crainic R
    Virology; 1993 Sep; 196(1):199-208. PubMed ID: 8102826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory tests for live attenuated poliovirus vaccines.
    Wood DJ; Macadam AJ
    Biologicals; 1997 Mar; 25(1):3-15. PubMed ID: 9167004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan.
    Yoshida H; Horie H; Matsuura K; Miyamura T
    Lancet; 2000 Oct; 356(9240):1461-3. PubMed ID: 11081527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of new approaches to poliovirus vaccine neurovirulence tests.
    Wood DJ
    Dev Biol Stand; 1996; 86():79-83. PubMed ID: 8785995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative mutant analysis of viral quasispecies by chip-based matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry.
    Amexis G; Oeth P; Abel K; Ivshina A; Pelloquin F; Cantor CR; Braun A; Chumakov K
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12097-102. PubMed ID: 11593021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.